Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women with Metastatic Non-Squamous NSCLC

被引：0

作者：

Young, P. ^{[1
]}

Marquez, D. ^{[1
]}

Noor, Z. ^{[1
]}

Callahan, R. ^{[1
]}

Jones, B. ^{[1
]}

Wong, D. ^{[1
]}

Goldman, J. W. ^{[1
]}

Applebaum, S. ^{[1
]}

Rausch, R. ^{[1
]}

Yanes, C. ^{[1
]}

Bueno, S. ^{[1
]}

Garban, N. ^{[1
]}

Elashoff, D. ^{[2
]}

Garon, E. ^{[3
]}

Pietras, R. ^{[4
]}

机构：

[1] Univ Calif Los Angeles, Hematol Oncol, Santa Monica, CA USA

[2] Univ Calif Los Angeles, Med, Los Angeles, CA USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Med Hematol Oncol, Los Angeles, CA 90095 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

estrogen receptor; Exemestane; NSCLC;

D O I：

10.1016/j.jtho.2018.08.661

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-104

引用

页码：S504 / S504

页数：1

共 50 条

[21] THE EFFECT OF PEMETREXED CONTAINING REGIMES ON OVERALL SURVIVAL IN NON-SQUAMOUS NSCLC
Stevens, R.
Booth, H.
Button, M.
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S74 - S74
[22] Phase Ib/IIa safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous NSCLC with/without STK11 mutations
Veluswamy, R.
Bhalla, S.
Mehra, R.
Gligich, O.
Garassino, M. C.
Oliva, C.
Gorcea-Carson, C.
McCracken, N.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S85 - S85
[23] Pemetrexed, Carboplatin and Bevacizumab in Patients with Non-Squamous NSCLC without or with Activating EGFR Mutation (CJLSG0909/0910)
Kimura, Tomoki
Taniguchi, Hiroyuki
Ogasawara, Tomohiko
Kondo, Masashi
Takeyama, Yoshihiro
Yamamoto, Masashi
Shindoh, Joe
Hataji, Osamu
Yoshida, Norio
Kojima, Eiji
Imaizumi, Kazuyoshi
Tanikawa, Yoshimasa
Yamada, Yoshiyuki
Ikeda, Takuya
Ichikawa, Motoshi
Hasegawa, Yoshinori
Saito, Hiroshi
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S548 - S549
[24] Anlotinib plus carboplatin/pemetrexed in treatment-naive advanced non-squamous NSCLC: An open-label, randomized, phase II study
Guo, R.
Gao, W.
Li, J.
Liu, Y.
Liu, X.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S801 - S801
[25] Carboplatin-Pemetrexed Combination in Elderly Patients with Advanced Non-Squamous Non Small Cell Lung Cancer (NS-NSCLC)
Vazquez, Sergio
Carmen Areses, Maria
Nunez, Natalia F.
Alonso Herrero, Ana
Covela Rua, Marta
Villanueva Silva, Maria J.
Afonso-Afonso, Francisco J.
Esquerdo Galiana, Gaspar
Lazaro Quintela, Martin
Garcia Mata, Jesus
Anido Herranz, Urbano
Casal Rubio, Joaquin
Firvida Perez, Jose L.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S657 - S657
[26] PEMETREXED AND CARBOPLATIN VERSUS DOCETAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
Ganju, Vinod
Pereira, Jose
Kim, Joo-Hang
Magallanes, Manuel
Lee, Dae-Ho
Wang, Jie
Martinez, Luis
Barraclough, Helen
Van Kooten, Maximiliano
Orlando, Mauro
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S417 - S418
[27] Phase II Trial of Carboplatin, Pemetrexed, Bevacizumab in Advanced non-Small Cell (non-Squamous) Lung Cancer
Guarino, Michael J.
Masters, Gregory A.
Biggs, David D.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S698 - S698
[28] Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients.
Dowlati, Afshin
Belani, Chandra Prakash
Simon, George R.
Chao, Heman
Piha-Paul, Sarina Anne
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[29] Pemetrexed maintenance therapy in advanced non-squamous NSCLC: a single institution experience
Lunghi, A.
Mazzoni, F.
Petreni, P.
Vannini, A.
Brugia, M.
Calamai, V.
Di Costanzo, F.
ANNALS OF ONCOLOGY, 2015, 26 : 88 - 89
[30] Necitumumab for patients with non-squamous NSCLC: uninspiring results
Zhou, Fei
Zhou, Caicun
LANCET ONCOLOGY, 2015, 16 (03): : 246 - 247

← 1 2 3 4 5 →